Introduction
The sixth biennial Chemical Protein Synthesis Meeting was held on June 16th-19th, 2015 in sunny St. Augustine, Florida. In attendance were 93 scientists from 17 countries, representing academia and the pharmaceutical andb iotechnology sectors. The meeting featured 33 talks by leaders in the field of protein chemistry,a nd al ively posters ession with over 30 presenters. The organizers, Philip Dawson (The Scripps Research Institute), Seth Horne (University of Pittsburgh), andS tephen Kent (Universityo fC hicago) succeeded in extending this meeting's excellent tradition of bringingt ogether both emerging and established investigators to share their latest discoveries in the broad fields of peptidea nd protein chemistry.T he diverse topics presented ranged from the optimization of peptides as therapeutics and cellular delivery agentst om ethods to assemble proteins site-specifically modified by ubiquitin,a nd the intracellulara ssembly of covalently modified semisynthetic chromatin.
Chemical protein synthesis and semisynthesis are powerful tools that provide access to targets with biologically relevant post-translational modifications (PTMs) in quantities that often remain inaccessible to current molecular biological strategies. Since its introduction by Kent and co-workers in 1994, native chemicall igation( NCL) has proven to be an invaluable componento fm anyp rotein synthesis efforts. [1] The simplicity of obtaining full-length proteins with precisely defined PTMs by ligating( from the Latin ligatus "to join") two strategically chosen protein fragments by means of an ative amide bond has led to the widespreadu se of NCL. Many innovative adaptations of NCL, such as small molecules that facilitatel igation and then find use as handles for purification or as activitybased probes, and techniques that convert multistep ligations into efficient one-potreactions were am ajor thrustoft he sixth CPS.
[2] Bio-orthogonal strategies such as the popularH uisgen 1,3-dipolar cycloaddition( the click reaction), [3] which permits peptides to be joined to any number of targets and the incorporation of unnatural amino acids bearing NCL-or click-ready groups were the focus of several presentations. [4] In combination with classical solid-phase peptide synthesis (SPPS) and well-establishedr ecombinant protein production techniques, the exciting technologiesd escribed at the sixth CPS promised synthetic access to countless proteins and peptides of interest to the biological and therapeutic research communities.
The meeting began with aw arm welcome reception and the keynote address delivered by Ashraf Brik (Technion Israel Institute of Te chnology,I srael) entitled "Recent developments in the synthesis of unique analogues of free and anchored ubiquitin chains". Ubiquitin (Ub) is one of many molecules covalentlya ppended to proteins in living cells. In contrast to smaller PTMs such as phosphorylation,m ethylation, and acetylation, the large size and multiple surfaces of Ub allow it to perform different context-dependent functions. These include signaling atarget'sintracellular localization,changingatarget's binding partners, and regulating enzyme activity.Afamily of over 600 ligase enzymes are involved in the site-specific attachment of Ub to protein targets, but only ah andful of these have been characterized thus far.T his poses as ignificant challenge when attempting to obtain ubiquitylated proteins in sufficient amounts for biochemical investigations. Brik's talk addressed this challenge while describing impressive recent advances by his group in the synthesis of phosphorylated diubiquitin, and studies addressing the effect of this newly discoveredu biquitin modification on the recognition of ubiquitin by the enzymatic machinery responsible for cleaving ubiquitin chains. [5] In addition, Brik also described efforts to devise new synthetic approaches for the preparation of polyubiquitylated proteins for use in av ariety of biochemical and biophysical studies. [6] His group's success in appending pre-assembled chains of ubiquitin to the model protein a-globin by at hioldirectedc onjugation strategy revealed ag eneral methodt hat should pave the way for mechanistic studies of the roles for protein polyubiquitylation. [6, 7] Novel chemical strategies for protein synthesis Canonical NCL involves ac hemoselective reactionb etween a C-terminal thioester on one polypeptide fragment and an Nterminal cysteine on another.T he efficient preparation of an activatedt hioester at the Cterminus of ap eptide by SPPS remains ac hallenge. To address this, Ryo Okamoto (Osaka University,J apan) presented an approachi nw hich ap eptidei s S-thiocarbonylated atc ysteinea nd subsequently treated with N-acetylguanidine. The resulting peptidyl-N-acetylguanidine is readily converted to an a-thioester,o ri ss uitable for direct use in ligationr eactions containing the alkyl thiol additive sodium 2-mercaptoethanesulfonate (MESNa). [8] Oleg Melnyk( University of Lille, France) introduced the selenium analogue of the SEA group, the bis(2-selenylethyl)amino (SeEA) moiety,a salatent selenoester.I nal igation mixture containing multiple peptide fragments, alkylthioester,S EA, and SeEA functionalities can be activateds pecifically,a nd in sequential order,b yc ontrolling the reductive power of the ligationm ixture,t hereby allowing elegant, one-pot assemblies of cyclic or branched peptides. [9] One-pot, multisegmentN CL was also addressed by Thomas Durek (The University of Queensland, Australia), who described the synthesis of disulfide rich, venom-derived peptides and characterization of their structures. [10] Richard Payne (The University of Sydney,A ustralia) delivered the 2015 MedChemComm Emerging Investigator Lectureo nt he development of general synthetic routes toward buildingb locks for thiol-derived amino acids and their utilization in ligationr eactions. Post-ligation conversion to an atural amino acid is often achieved by metal free-radical-mediated desulfurization, [11] which is unfortunatelyi ncompatible with the common NCL thiol catalyst, 4-metcaptophenylacetic acid (MPAA). In order to combine ligationa nd desulfurization into ao ne-pot process, Payne employed2 ,2,2-trifluoroethanethiol (TFET) as the NCLt hiol additive to achievel igation rates near that affordedb yM PAAw ithout any detrimental effect on the desulfurization reaction.
[2b]
An alternative one-pot ligation-desulfurization method was presented by Christian Hackenberger (HumboldtU niversität zu Berlin,G ermany);a nd it was demonstratedo nt he unstructured Taup rotein,w hich is closely associated with the pathology of Alzheimer's disease. [12] Hackenberger's method employed ap hotocleavable biotin tag at the Cterminus of the Taul igation product as at racelessp urification handle that is compatible with free-radical desulfurization on streptavidin-conjugated resins.
An on-resin ligation andp urification strategy was presented by Agns Delmas (CNRS-OrlØans, France). Following SPPS, a peptide fragment is linked to aw ater-compatible resin for a series of click triazole ligations. [13] Importantly,t he resin linker is compatible with the ligationc hemistry as well as enzymatic glycosylation of the protein ligationp roduct, MUC1, yet can still be cleaved efficientlyi nt he presence of sensitive glycosidic bonds. This is an exciting development for the rapid synthesis of glycosylated proteins. Serine/threonine ligation, an alternative to thiol-based NCL, was presented by Xuechen Li (The University of Hong Kong). [14] In this method, ap eptide generated by traditional 9-fluorenylmethoxycarbonyl (Fmoc-) SPPS and bearing aC -terminal salicylaldehyde ester was reacted with as econd peptide bearing an N-terminal serine or threonine residue. Acidolysis of the formed N,O-benzylidine acetal at the ligation site generated the native serine or threonine. The high abundance of serine and threonine in proteins, relative to cysteine, provides significantly more options when selecting the site of chemical ligation.
Elucidating functions of post-translationalm odifications
The synthesis of post-translationally modified target proteins or peptides is necessitated when recombinant or in vitro enzymatic methods do not yield product in the quantity,p urity,o r site-specificity required for biochemical or biophysical assays. Use of the ligationa uxiliary 2-aminooxyethanethiol to site-specificallya ppend ubiquitin to the e-amineo fl ysine was presented by Champak Chatterjee( University of Washington,U SA). [2a] Surprisingly,r etention of the ligationa uxiliary in ubiquitylated substrates conferred stabilityt ot he~100 deubiquitylating enzymes( DUBs)i nc ellular lysates;t his might be useful in lysate pull-downe xperiments with these compounds. Huib Ovaa (Netherlands Cancer Institute, The Netherlands) presented an ovel and unexpected property of as ubset of deubiquitylating enzymes. His group has developed active-site-directed probesf or DUBs that employ terminal alkynes. The alkyne probe displays unexpected reactivity with the active-site cysteine of DUB proteases to form av inyl thioether that covalently traps the DUB. [15] Such activity-based probesa re invaluable for determining the substrate specificity of enzymes,e ven within complexm ixtures, anda re especially useful for identify- www.chembiochem.org ing the enzymes responsible for the addition and removal of PTMs, many of which remainunidentified.
Improvements in assays to evaluateknown enzymest hat act on PTMs were also described. Dirk Schwartzer (University of Tübingen,G ermany) presented his group's research on histone deacetylases (HDACs), which are key regulators of epigenetics and chromatin activity.T hey have established new chemical probes, based on methodologies of modern peptide and protein chemistry,f or interrogating the substrate selectivity and composition of endogenous HDAC complexes. The utility of their approach was demonstratedi nd etermining the preference of HDAC8 for deacetylation at specific lysiner esidues in the Cterminus of p53. [16] Another PTM that garnered much attention for its complexc ellular functions ands ynthetic challenges was protein glycosylation. MatthewP ratt (Universityo f SouthernC alifornia, USA) focused on O-linked b-N-acetyl glucosamine (O-GlcNAc). O-GlcNAcylation is the addition of the single monosaccharide N-acetyl glucosamine to intracellular proteins in metazoans and plants. Pratt's group used cuttingedge semisynthesis to prepare a-synuclein site-specifically modified with ap hysiologically relevant O-GlcNAc. They demonstrated that this modification has ad ramatic inhibitory effect on the aggregation and toxicity of the protein;t his has important implications for ensuring the persistence of a-synuclein O-GlcNAcylation in Parkinson's disease. [17] Glycosylated proteins have long been difficult targets for the synthetic community [18] due to the diverse nature of glycosidic linkages, monosaccharide compositiona nd polysaccharide chain lengths, and the formation of branched chains. Christian Becker (University of Vienna, Austria)a nd Carlo Unverzagt (University of Bayreuth, Germany)d escribed tackling thesec hallenges with two different strategies that have expanded chemical access to glycosylated proteins. The Beckerg roup recently reported as ynthetic method for glycosylated protein ligation based on aP EGylated photocleavable auxiliary,a nd demonstrated its utility by generating al ibrary of site-selectively Oglycosylated MUC1 variants with differentg lycosylation patterns. [19] Unverzagt shared his group's progress toward the extremely challenging semisynthesis of biologically active glycoforms of human IL-6 by NCL of recombinanta nd synthetic glycoprotein fragments. Key to their success wasa ne fficient refolding method that gave rapid access to libraries of IL-6 glycoforms in high yield and purity. [20] Ratmir Derda (University of Alberta,C anada) discussed the assembly and screeningo f genetically encoded libraries of chemically modified peptides on the surface of the bacteriophage M13. Using this highthroughput approach, his teamd iscovered hybrid peptide-carbohydrate ligands that specifically bind to carbohydrate binding proteins (lectins). [21] Dissecting biomolecular interactions with protein chemistry
In addition to interrogatingP TMs, chemical protein synthesis has also been applied to directly investigate protein-protein interactions (PPIs) and to facilitate structure-activity studies of PPI inhibitors. Wuyuan Lu (University of MarylandS chool of Medicine, USA) discussed his use of protein semisynthesis techniques to investigate the basis of high-affinityp eptidei nhibitiono fthe p53-MDM2/MDMX interaction, [22] and presented recentw ork on the inhibition of this interaction by stressinduced MDM2/MDMXp hosphorylation. By synthesizing the site-specifically phosphorylated p53 binding domains of MDM2 and MDMX, Lu's group was able to show that phosphorylation at as ite different from that previously identified is in fact responsible for disruptingb inding. Yaowen Wu (Chemical GenomicsC entre of the Max Planck Society,G ermany) described an ovel protein N-to-N and C-to-C ligations trategy to trap weak interactions, in which small molecules with thiol or thioester moieties can link two protein terminio nly when weaki nteractions hold the proteins in close proximity.U sing this strategy,h is group prepared ac ovalentcomplex between the yeast Rab family GTPase Ypt1 and Rab GDP dissociation inhibitor (GDI) that mimics the transienti ntermediate of the prenylated Ypt1-GDI interaction. This served as as ubstrate for GDI-displacementf actor (GDF) and gave insights into the mode of action of GDF. [23] To mG rossmann (Chemical Genomics Centre of the Max PlanckS ociety, Germany) presented his group's efforts to use PPIs to drive efficient chemical ligation. Ad omain of the CREB bindingp rotein (CPB) that is capable of binding two different peptide sequences simultaneously served as at emplate to align the Nterminio fp eptidyl ligands and increase the rate of al igation reactionb etween them 6200-fold. [24] This concept was then applied to selectively label proteins in ac ell lysate.
Protein chemistry in living cells
Te chniques that permitt he manipulation of proteins within intact cellsa re useful for studying complexp rocesses that might not be accurately recapitulatedi nv itro. One such process is the biochemical crosstalk between epigenetic PTMs, or "marks", in chromatin.
[25] To mM uir (Princeton University,U SA) described the use of ultrafast split inteins, single-turnover enzymes that catalyze protein ligation (also called protein splicing), to incorporate ubiquitylatedh istone H2B into chromatin in live cells. [26] With this technique, his group was able to show that ubiquitylation of H2B leads to an increase in methylation at Lys79 in histone H3.
Kathrin Lang (Technische Universität München,G ermany) discussed genetic-code expansion in Escherichia coli and mammalianc ells to incorporateu nnatural amino acids bearing strained alkene or alkyne moieties into proteins. [27] These groups,w hich reactr apidly with tetrazine conjugates by an inverse-electron-demand Diels-Alder cycloaddition,w ere utilized to fluorescently label proteins in vivo for imaging by super-resolution microscopy techniques. GonÅalo Bernardes( University of Cambridge,U K) describedt he successful construction of artificial ruthenium dicarbonyl metalloproteins that spontaneously release biologically functional carbon monoxide in live cells and mice. [28] Bernardes also discussed studies utilizing albuminbased artificial metalloproteins that accumulate and selectively deliver CO to tumors in mice;t his permitted investigation into the poorly understood anticancer properties of toxic CO. Ned Budisa (Technische Universität Berlin, Germany) shared his group's exciting work towards the evolution of synthetic cells with alternative biochemical building blocks. [29] In al ongterm evolution experiment,t ryptophan auxotrophic E. coli cells were gradually forced to adapt to an alien environment by reducing the concentration of tryptophan and maintaining aconstant concentration of new substrate, l-b-(thieno[3,2-b]pyrrolyl)alanine. The experiment yielded bacteria capable of using this new amino acid for all their cellular processes. Not only does this open the way to engineering new spectral, thermodynamic, and pharmacological properties into existing proteins, but it also showcases the potential of E. coli in potentially colonizing hostile environments.
Chemical synthesis of mirror-image peptides and proteins
Due to their protease resistancea nd low immunogenicity,p roteins and peptidesc ontaining mirror-image a-d-amino acids are attractive as therapeutic agents. With this in mind, Tilman Hackeng (Maastricht University,T he Netherlands) presented efforts to developad-peptide inhibitoro ft issue factor pathway inhibitor (TFPI), ap rotein that inhibits normal blood clotting and leads to uncontrolledb leeding in hemophilia. [30] Lei Liu (TsinghuaU niversity,C hina) presented work on the use of his group'sp eptide C-terminala cylhydrazide method of synthesizing photocaged chemokines and d-amino acid-containing mirror-image versions of immune checkpoint proteins. [31] These synthetic proteins were used to study cell migration under spatiotemporal control and towardt he development of d-peptide antagonists for canceri mmune therapy.
As ubset of cellular proteins can only adopt the correct folded structure with the assistance of chaperone proteins such as GroEL and Hsp90. [32] Given their opposite chirality to natural proteins, it is possible that d-proteins would require the mirror-image version of naturallyo ccurring molecular chaperones to fold correctly.M ichael Kay (Universityo fU tah School of Medicine, USA) addressed this question by investigating the ability of the GroEL/ES chaperone complex to fold am irror-imagep rotein. [33] His group synthesized the 312-residue protein DapA,w hich requiresG roEL/ES-mediated folding, in both l-a nd d-enantiomeric forms and determined that, surprisingly,G roEL/ES can fold both diastereomers.S uch detailed mechanistic studies support an onspecific hydrophobic interaction model for chaperone activity,a nd provide av aluable tool for correctly folding d-proteins for mirror-image drug development and synthetic biology applications.
Protein and peptide therapeutics with unusual topologies N-to-C-terminally conjugated, or cyclic, peptides are biologically active, thermally stable and resistant to enzymatic degradation;t his makes them attractive as therapeutic agents. David Craik (The University of Queensland,A ustralia) presenteda methodt og enerate cyclotides, smalld isulfide-richc yclic peptides that can serve as scaffolds for bioactivem olecules. [34] Craik's group utilized sortase A, ab acterial transpeptidase, to cyclize av ariety of small disulfide-richp eptides ranging in size from 14 to 29 amino acids and containing up to three disulfide bonds.O ne feature of cyclotidest hat is particularly appealing is that they occur naturally in numerous plant species including the pea, potato, and grass families. [35] Ap leasantv ision for the future of pharmaceutically active cyclotides could indeed be their production in current cash crops, although several issues including dosagea nd bioavailability would need to be addressed prior to commercialization. Les Miranda (Amgen, USA) presented efforts toward engineering selective analogues of the GpTx-1 tarantula venom peptidea ntagonist of sodium channel Na V 1.7, an important channel found in pain-sensing neurons.P ositional alanines canning of GpTx-1, which contains three disulfide linkages in the inhibitory cystine knot (ICK) motif, [36] led to the identification of an analoguet hat is nearly ten times more potent ando ver 1000t imes more selective than wild-type GpTx-1. [37] Mohamed Marahiel (Philipps-UniversitätM arburg, Germany) presented his work with lasso (or lariat) peptides that are proteolytically and thermally stable bacterial natural products with therapeutic potential. The unique defining structural feature of lasso peptides is am acrolactamr ing formed by an isopeptide linkage between the peptideNterminus and an aspartate or glutamate side chain. The C-terminal tail is threaded through the macrolactam ring and held in place by bulky residues above andb elow the plane of the ring. Marahield iscussed his group's latest findings on lasso peptides, their biosynthesis, and their physicochemical properties, including the proposed mechanism through which the precursor peptide is enzymatically processed into am aturel asso peptide. [38] He also presented new analytical tools to assess and prove the lasso topology withoutthe requirement for complete structuralelucidation.
Rob Liskamp (University of Glasgow, UK) discussed his group's work in the synthesiso fp rotein mimetics consisting of discontinuous epitopesc onnected to ac entral scaffold. [39] He described the efficient convergents ynthesis of scaffolds presenting cyclic peptides, which can be used as individual protein mimics or as targeted synthetic vaccines. Dendrimersa lso provide as caffold on which to present multiple therapeutic ligands.P aul Alewood (The University of Queensland, Australia) discussed dendrimers developed in hisg roup that incorporate the a7-nicotinic receptor blocker a-conotoxin ImI (a-ImI). [40] The dendrimers were synthesized by aC u I -catalyzed cycloaddition of azide-modified a-ImI to an alkyne-modified polylysine dendron. Alewood demonstrated that the multimeric display of conotoxins significantly enhances potency against areceptor relative to the monomeric ligand.
Improving the stability and delivery of protein-based biologics
Protein-based biologicsm ust circulate in the bloodstream long enough to achievet heir therapeutic goals. Hence, resistance to proteolysis and diminished renal clearance are two highlyd esirable properties. The modification of proteins with long-chain poly(ethylene glycol)i sawell-established strategy that significantly increases their half-lives in biological fluids. [41] However, the precise position in ap rotein where PEG may be appended ChemBioChem 2015 ChemBioChem , 16,2531 ChemBioChem -2536 www.chembiochem.org is typicallyo nly empirically determined. Joshua Price (Brigham Young University,U SA) presented at hought-provokings tructure-guided method for predicting sites on ap rotein that might confer stabilizationu pon PEGylation. [42] This methodology correctly predicted al ocation in the Src kinase SH3 domain where PEGylation led to conformational stabilization and aconcomitanti ncrease in resistance to proteolysis.U nderstanding the principles that govern site-specific stabilization of proteins by PEGylation will undoubtedly have at remendous impact in the rapidly growingb iologics industry.
Product homogeneity and manufacturing efficiency are two key factorsi nt he successful commercialization of biologics. With this in mind, Anouk Dirksen( Pfizer Inc.,U SA) highlighted the significant improvements that have been made in developing the conjugationp rocess of aF GF21 protein-antibody conjugate in order to make it commercially viable. [43] This conjugate reached clinical trials for metabolic disease indications. Thorough evaluationa nd ag reater understanding of the key processp arameters, focused on enhancing the stability and quality of reaction intermediates, greatly improved the overall yield and final product purity.T his allowed for as ignificant reduction in the consumption of materials such that the projectionsm ade for ac ommercial process were exceeded.
Many protein-and peptide-based drugs must cross the cell membrane before reaching their intended targets, and methods to cross this barrierw ere also presented. Bradley Pentelute (Massachusetts Institute of Te chnology,U SA) described the use of protective antigen (PA) from anthrax toxin to deliver a d-polypeptide cargo into the cytosol of mammalian cells. [44] When conjugated to the Cterminus of the PA bindingd omain of anthraxl ethal factor,L F N ,t he cargo was efficiently delivered and able to disrupt protein-protein interactions in cancerc ells leadingtoa poptosis.
Outlook
The sixth CPS meeting emphatically highlighted the seemingly endlessp otential of peptidea nd protein chemistry when applied to understanding and controlling complex biological processes. As an enablingt ool that provides facile access to naturally occurring proteins and their unnatural analogues, chemical protein synthesis will no doubt continue to inspirem any new mechanistic investigations and rational engineering approaches in the years ahead. We look forwardt oh earing about these at the seventh CPS meeting to be heldi nH aifa, Israel.
